the value of in vitro diagnostics n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
The Value Of In-vitro Diagnostics PowerPoint Presentation
Download Presentation
The Value Of In-vitro Diagnostics

Loading in 2 Seconds...

play fullscreen
1 / 14

The Value Of In-vitro Diagnostics - PowerPoint PPT Presentation


  • 370 Views
  • Uploaded on

Forum “For Healthy Life” December 9-10, 2013, Moscow. The Value Of In-vitro Diagnostics. Healthcare challenges in the 21 st century for governments & hospitals & how in-vitro diagnostics can contribute to overcoming these. Regina Kloss-Wolf

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'The Value Of In-vitro Diagnostics' - awen


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
the value of in vitro diagnostics

Forum “For Healthy Life”

December 9-10, 2013, Moscow

The Value Of In-vitro Diagnostics

Healthcare challenges in the 21st century for governments& hospitals & how in-vitro diagnostics can contributeto overcoming these

Regina Kloss-Wolf

Director Global Strategic Health Initiatives, Abbott Laboratories

the healthcare world in the 21 st century having to do more with less
The Healthcare World In The 21st Century:Having To Do More With Less

Demographic change reinforces rise of NCDs

  • Economic
  • Reality:
  • Decreased healthcare budget
  • Healthcare
  • Reality:
  • Increased
  • healthcare demand

Challenge #1

Challenge #2

Ageing

population

Rise

of NCDs

Healthcare reality: increased demand for healthcare

healthcare reality challenge 1 population ageing
Healthcare Reality - Challenge 1:Population Ageing

60+yrs

Russia

2050: 37%

2025: 26%

2000: 18%

Sources: United Nations, Population Facts, Population Ageing and the non-communicable diseases, April 2012, accessed 25 November 2013.

United Nations, World Population Ageing 1950-2050, accessed 25 November 2013.

http://www.un.org/esa/population/publications/worldageing19502050/pdf/173russi.pdf

healthcare reality challenge 2 non communicable diseases key f acts
Healthcare Reality - Challenge 2:Non Communicable Diseases - Key Facts

“Non Communicable diseases

(chronic diseases) are not

passed from person to person.

They are of long duration &

generally slow progression”

Between 70% & 80% of

Europe’s healthcare costs

are spent on chronic care,

amounting to €700bn

NCDs cause more than

36 million deaths worldwide

– 63% of all mortality

Early intervention may

enable early detection &

hence contribute to cost-reduction

Sources: WHO, factsheet on Chronic Diseases, accessed 25 November 2013. WHO, factsheet on Noncommunicable diseases, accessed 25 November 2013.

EPHA, Extend healthy years by tackling chronic diseases in a life-course approach, accessed 25 November 2013.

healthcare reality challenge 2 rise of cardio vascular diseases associated costs
Healthcare Reality - Challenge 2Rise Of Cardio Vascular Diseases & Associated Costs

CVDs

23.3 million of people dying of CVDs

Cost of CVDs:$1,044bn

Cost of CVDs: $863bn

17.3 million people dying of CVDs

CVDS

2008

2008

2010

2010

2030

2030

Sources; AIHW, Why are mortality data important?, accessed 25 November 2013.

World Economic Forum, Non-communicable Diseases to cost $47 trillion by 2030, New Study Released Today, accessed 25 November 2013.

World Heart Federation, The cost of CVD, accessed 25 November 2013.

WHO, factsheet on Cardiovascular Diseases,, accessed 25 November 2013.

healthcare reality challenge 2 rise of cardio vascular diseases associated costs1
Healthcare Reality - Challenge 2Rise Of Cardio Vascular Diseases & Associated Costs

Russia

  • CVDs account for 57% of all deaths
  • NCDs account for 90% of all deaths
  • Cost of CVDs:
  • 3% of GDP

CVDs

NCDs

RUR

2012

2006-2009

2012

  • Source: Petrukhin IS, Lunina EY. Cardiovascular disease risk factors and mortality in Russia: challenges and barriers. Public Health Reviews. 2012;33:436-49
so what does the rise of ncds mean
So What Does The Rise Of NCDs Mean?

The worldwide rise of chronicNon Communicable Diseases:a slow-motion catastrophe

Margaret Chan

WHO Director General

increasing use of clinical g uidelines and quality measurements g lobally
Increasing use of Clinical Guidelines and Quality Measurements Globally

How Do IVDs Fit Into This ?

Cost-effectiveness

Clinical outcomes

Hospital bed occupancy rate

Mortality

rates

Unplanned readmission

Cost per discharge

Average waiting time for patient

Length of stay

slide9

IVD

Case Studies

How can IVDs contribute to overcoming this challenge?

the diagnostics paradox recognised important role but low investment
The Diagnostics Paradox:Recognised Important Role, but Low Investment

70%

Early diagnosis & treatment stops NCDs progressing into costly, crippling complications & premature death

Medical decisions are based on IVDs

Healthcare budget spent on IVD’s

2%

NCD Alliance

10

Sources: NCD Alliance, Discussion Paper No. 3 Geneva 2011, accessed 25 November 2013.

EDMA answer to the European Commission consultation on Community Action on Health Services, 31 January 2007, p.2

ivds one of the key tools in diagnostics
IVDs: One Of The Key Tools In Diagnostics

Disease prevention&

Population screening

Monitoring of prescribed treatments

In Vitro Diagnostics are usedalongside the healthcare pathway

Assessment

of medical interventions

Diagnosis, treatment selection

& Prognosis

case1 early diagnosis of heart failure and differentiation from other diseases causing dyspnoea

Biomarker helpsto diagnose congestive heart failure

Case1: Early diagnosis of heart failure and differentiation from other diseases causing dyspnoea

The impact

on quality measurements

  • The challengeManagement of patients with acute Dyspnoea

BNP

(B-type NatriureticPeptide)

HF is the most frequent diagnosis associated with 30 day readmission

-10%

Admission rate

30

Treatment

cost

Cost per discharge

Cost per patient

Length of stay

Mortality

$-1.854

-2.2

12

case 2 taking the right decision in case of heart attack in patients with acute chest pain

Earlier triage of patients, already after 2-4 hrs.

with hsTroponin

vs. 6-12 hrs.

Case 2: Taking The Right Decision In Case Of Heart Attack In Patients With Acute Chest Pain

The impact

on quality measurements

The challengeCorrect triaging

hs Troponin

7-20%

Only 7-20% of patients who present with chest pain in the ED are confirmed for diagnosis of myocardial infarct

40%

More confident rule out for up to 40 % with suspected acute coronary syndrome

Waiting times

Cost per discharge

Waiting times

Cost per discharge

Better allocation

13

conclusion
Conclusion
  • The burden of the ageing world population and NCDs will continue to rise.
  • IVDs play an important role in optimizing care and minimizing cost
  • IVDs are critical to the successful implementation of clinical guidelines and quality measures.